ISS describes a category of children with severe short stature and poor growth velocity in the absence of an identifiable cause. After a thorough evaluation has been conducted, a number of therapeutic options may be considered. The approval of ISS as an indication for GH treatment poses further challenges in optimizing management of these patients.